|
Sunitinib approved in UK |
| Posted by Julie Royster (juliecontent) on May 29 2009 |
NICE, the health agency in the United Kingdom, has made a decision to allow provision of sunitinib to GIST patients.
Quoting a story on the website DocGuide, "The National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document (FAD) recommending sunitinib malate (Sutent) as a second-line treatment for patients with advanced gastrointestinal stromal tumour (GIST). The guidance states that sunitinib malate is recommended for reimbursement as a treatment option for patients with advanced GIST after disease progression on or intolerance to imatinib mesylate, and who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1."
Link to the full story at DocGuide.com
Last changed: May 29 2009 at 1:05 PM
Back
